Exploratory Study Evaluating the Relevance of [68Ga]Ga-PentixaFor for Initial Staging and Detection of Minimal Residual Disease in Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation Less Than 66 Years Included in the Prospective IFM 2020-02
Latest Information Update: 22 Nov 2023
At a glance
- Drugs 68Ga PentixaFor (Primary)
- Indications Multiple myeloma
- Focus Diagnostic use
- Acronyms PENTI-MIDAS
Most Recent Events
- 13 Nov 2023 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 02 Dec 2022 New trial record